{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-133091","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.177767+00:00","generated_at":"2026-05-29T08:43:27.433351+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Aptevo unveils preclinical bispecific APVO442 for prostate cancer; targets $14B market","bullets":["APVO442 is a PSMA x CD3 bispecific antibody designed to treat prostate cancer.","First molecule developed using Aptevo's ADAPTIR-FLEX platform.","Prostate cancer market valued at ~$14B, expected to grow to $24B+ over ten years.","Preclinical studies show tumor localization and reduced binding to circulating immune cells.","Aims to address advanced-stage prostate cancer with improved safety and efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-133091","json":"https://secwatch.observer/filing/0000950170-24-133091.json","markdown":"https://secwatch.observer/filing/0000950170-24-133091.md","text":"https://secwatch.observer/filing/0000950170-24-133091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024133091/0000950170-24-133091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024133091/apvo-20241204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T08:43:27.433351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}